While clinical development has focused on metabolic diseases such as diabetes and NAFLD, emerging evidence indicates that FGF21 also exerts antitumor effects in cancers including hepatocellular and prostate carcinoma, potentially through modulating autophagy, glycolysis, and ferroptosis (22–26). The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.